Last reviewed · How we verify
MUC1 Peptide Vaccine
At a glance
| Generic name | MUC1 Peptide Vaccine |
|---|---|
| Sponsor | Finn, Olivera, PhD |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ (PHASE1)
- Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC) (PHASE1, PHASE2)
- TG4010 and Nivolumab in Patients With Lung Cancer (PHASE2)
- Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery (PHASE1)
- Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer (PHASE1, PHASE2)
- Vaccine Therapy in Treating Patients With Newly Diagnosed Advanced Colon Polyps (PHASE2)
- MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer (PHASE1)
- Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MUC1 Peptide Vaccine CI brief — competitive landscape report
- MUC1 Peptide Vaccine updates RSS · CI watch RSS
- Finn, Olivera, PhD portfolio CI